Back to Search Start Over

Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Source :
Legal Monitor Worldwide. November 5, 2020
Publication Year :
2020

Abstract

Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx (secukinumab) on [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.640654318